Mitzi Joi Williams, MD, FAAN, medical director and CEO, Joi Life Wellness Neurology Clinic, addresses several reasons that have potential to delay a correct multiple sclerosis (MS) diagnosis in minority patient populations, including social determinants of health.
Mitzi Joi Williams, MD, FAAN, medical director and CEO, Joi Life Wellness Neurology Clinic, in an interview from this year’s American Academy of Neurology annual meeting, addresses several reasons that have potential to delay a correct multiple sclerosis (MS) diagnosis in minority patient populations, including social determinants of health (SDOH).
Transcript
Beyond SDOH, what might lead to a delayed MS diagnosis in minority and underserved patient populations?
I think that the biggest reason that we may see delay in diagnosis is social determinants of health. But I think also, there needs to be more education amongst the general medical community. When most of us came through training, we thought of MS as a disease of young white European women or women of European descent, and so because the symptoms of MS can mimic many other conditions—they often may resolve after a couple of weeks—it's important for people to think about MS in these populations and to recognize that anyone can get MS. And just like it may be high on the list for a young White woman presenting with certain symptoms, it should also be high on the list for people of Black and African American, as well as Hispanic and Latinx, descent.
Personalized Care Key as Tirzepatide Use Expands Rapidly
April 15th 2025Using commercial insurance claims data and the US launch of tirzepatide as their dividing point, John Ostrominski, MD, Harvard Medical School, and his team studied trends in the use of both glucose-lowering and weight-lowering medications, comparing outcomes between adults with and without type 2 diabetes.
Listen
Racial Differences in CA-125 Levels Tied to Ovarian Cancer Treatment Delays
April 17th 2025Black and American Indian women with ovarian cancer were less likely to have elevated cancer antigen 125 (CA-125) levels at diagnosis, resulting in delayed chemotherapy initiation and highlighting the need for more inclusive guidelines.
Read More
Navigating Sport-Related Neurospine Injuries, Surgery, and Managed Care
February 25th 2025On this episode of Managed Care Cast, we speak with Arthur L. Jenkins III, MD, FACS, CEO of Jenkins NeuroSpine, to explore the intersection of advanced surgical care for sport-related neurospine injuries and managed care systems.
Listen
Empowering Teams Begins With Human Connection: Missy Hopson, PhD
April 16th 2025Missy Hopson, PhD, Ochsner Health, discussed in detail the challenges of strengthening the patient-centered workforce, the power of community reputation for encouraging health care careers, and the influence of empowered workforces on patient outcomes.
Read More